A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome
Most Cited Paper
in Cell Adhesion Molecules Research
18 Months Post-Publication
Class of 2026
“A phase 3 randomized trial of mavorixafor, a CXCR4 antagonist, for WHIM syndrome”
A research intelligence initiative by Pepkio
pri.pepkio.com/top-papers/cell-adhesion-molecules-research/2026/
Topics
mavorixafor · CXCR4 antagonist · WHIM syndrome · CXCR4 gain-of-function variants · absolute neutrophil count · time above ANC threshold · absolute lymphocyte count · myelokathexis · annualized infection rate · total infection score · phase 3 randomized trial · neutropenia · lymphopenia · rare immunodeficiency
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Cell Adhesion Molecules Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/cell-adhesion-molecules-research/2026. Accessed 2026-07-21. Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459